A functional gene with improved immunity of sea cucumber
By developing WFDC protein and its engineered WFDC-WAP, combining lipopolysaccharides, peptidoglycans and mannans, the immunity of ginseng is significantly improved, and the safety and efficiency of immunity improvement in aquaculture is solved, especially for Gram Negative bacteria have significant antibacterial effects.
Patent Information
- Application Number
- CN202410744638.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-11
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-06-11
AI Technical Summary
There is a lack of safe and efficient method for improving immunity in ginseng farming. Existing methods such as the addition of Chinese herbal medicines and probiotics are toxic, costly, unstable, or lack targeting.
A functional gene-encoded protein (WFDC protein) has been developed, which has binding activity against lipopolysaccharides, peptidoglycans and mannans, and can significantly agglutinate and bactericidal, and is used to construct genetically engineered strains to improve immunity of ginseng. performance.
By distributing WFDC protein produced by engineered bacteria in the aquaculture environment of the aquaculture, the immunity of the aquaculture is significantly improved, providing effective protection against pathogenic bacteria, and especially significantly improving the antibacterial activity of the Gram-negative bacteria.
Smart Images

Figure CN118515739B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of functional genes, and in particular relates to a functional gene capable of improving the immunity of sea cucumbers. Background Art
[0002] Sea cucumber Apostichopus japonicus ) belongs to the phylum Echinodermata. It is dark brown cylindrical or spindle-shaped, with a slightly raised back and covered with conical fleshy spines, hence the name "sea cucumber". Sea cucumbers are widely distributed in shallow sea areas with gentle currents and abundant algae. They are high in protein, low in fat, and have a warming and tonic effect. They are one of the eight traditional aquatic delicacies and have extremely high nutritional and economic value.
[0003] With the expansion of sea cucumber farming and the increase in farming density, the problem of farming diseases has become more and more serious and has become the main bottleneck restricting the development of sea cucumber farming. As an invertebrate, sea cucumbers only have non-specific immunity and cannot develop aquatic vaccines to improve immunity like fish farming. At present, the main means of preventing and controlling sea cucumber diseases is to add Chinese herbal medicine, immune polysaccharides, probiotics and other immune enhancers during farming. However, various methods have certain problems and defects. Chinese herbal preparations such as Coptis chinensis, Scutellaria baicalensis, and Forsythia suspensa have direct bactericidal effects, but they have certain acute toxicity to sea cucumbers. The optimal addition concentration and formula of Chinese herbal preparations in feed need to be improved. Feeding feeds with added immune polysaccharides such as chitin and chitosan indirectly improves the immunity of sea cucumbers by improving the phagocytosis and enzyme activity of sea cucumber immune-related cells. However, it lacks specificity to diseases, has unstable effects, and has high feeding costs. Feeding feed supplemented with probiotics such as Bacillus and yeast improves the immunity of sea cucumbers by improving the intestinal flora of sea cucumbers and increasing the activity of immune-related enzymes. However, this method also has problems such as lack of targeting of diseases and unstable and unclear effects. At present, there is a lack of safe and efficient means to improve the immunity of sea cucumbers against related diseases. Therefore, it is very necessary to explore the genes related to the natural immune proteins of sea cucumbers, construct engineered bacteria that express genetically encoded immune-related proteins, and then industrially produce related antibacterial drugs. Summary of the invention
[0004] The purpose of the present invention is to provide a functional gene with the ability to improve the immune effect of sea cucumbers. The protein encoded by the functional gene and its specific gene fragment has binding activity to lipopolysaccharide, peptidoglycan and mannan: it has obvious agglutination and bactericidal effects on pathogenic bacteria of sea cucumbers, and can effectively improve the immune performance of sea cucumbers.
[0005] The present invention first provides a protein encoded by a functional gene (abbreviated as WFDC protein), the amino acid sequence of which is as follows:
[0006] MTRKTIPPVHEGQCPQVSAHLFPCRRHECEYDQHCEKHEKCCPTLCSGKKCQRAVNDLQTTATVSVTTETSRLSTLPIASCVNFTQLHTFISMNESLFTCQRSRCLQKRSHLPVCGTNGITFTNICRLIIANRTTSIPINMAYRGPCDGRATCHGAACSTGPQLNWEWIDGRIQGRLKDLNGGLNTPGEIPTNEKSLTSSELLSEYTTSGSSEVP (SEQ ID NO:3);
[0007] The functional gene described above has a nucleic acid sequence of one of its CDSs as follows:
[0008] ATGACAAGGAAAACAATACCCCCAGTTCATGAAGGCCAATGCCCACAAGTCAGTGCCCACCTGTTCCCTTGCCGAAGACATGAATGTGAGTACGACCAACACTGTGAGAAACATGAAAAGTGCTGCCCAACATTGTGTTCAGGCAAAAAGTGTCAAAGGGCTGTGAACGACCTGCAAACAACTGCAACTGTATCAGTAACCACGGAAACAAGCAGACTATCCACCCTACCAATAGCAAGTTGTGTAAATTTCACCCAGCTTCATACTTTCATCTCCATGAACGAGTCACTATTTACCTGCCAGCGGTCTAGATGCCTCCAAAAACGCAGTCACCTACCGGTATGTGGAACAAACGGTATTACTTTCACTAATATCTGCAGACTCATCATTGCAAACAGGACAACTTCTATTCCTATCAATATGGCCTACAGAGGACCATGTGACGGGAGAGCCACTTGCCATGGGGCAGCCTGTAGTACCGGCCCACAACTTAACTGGGAGTGGATTGATGGAAGAATTCAAGGACGCCTCAAAGATTTGAATGGTGGATTAAATACACCCGGAGAAATCCCCACCAACGAGAAATCCCTCACCAGCTCTGAATTATTGTCGGAATATACAACATCAGGCTCTTCAGAAGTACCTTGA (SEQ ID NO:2);
[0009] The present invention also provides a modified protein encoded by the functional gene (abbreviated as WFDC-WAP protein), the amino acid sequence of which is as follows:
[0010] HEGQCPQVSAHLFPCRRHECEYDQHCEKHEKCCPTLCSGKKCQRAV (SEQ ID NO:5);
[0011] Correspondingly, a nucleic acid sequence of its CDS is as follows:
[0012] CATGAAGGCCAATGCCCACAAGTCAGTGCCCACCTGTTCCCTTGCCGAAGACATGAATGTGAGTACGACCAACACTGTGAGAAACATGAAAAGTGCTGCCCAACATTGTGTTCAGGCAAAAAGTGTCAAAGGGCTGTG (SEQ ID NO: 4);
[0013] The present invention also provides a recombinant expression vector, wherein the CDS nucleic acid fragment of the above gene protein or its modified form is inserted into the recombinant expression vector;
[0014] The present invention also provides a genetically engineered strain carrying the above-mentioned recombinant expression vector.
[0015] The present invention also provides a use of the protein encoded by the functional gene or its modified form, which is used as an endotoxin lipopolysaccharide, peptidoglycan or mannan binder;
[0016] In another aspect, the present invention also provides the use of the protein encoded by the functional gene and its modified form in the preparation of products for inhibiting bacteria;
[0017] The bacteria include but are not limited to Staphylococcus aureus, Micrococcus luteus, Vibrio splendidus and Vibrio parahaemolyticus;
[0018] The present invention also provides another use of the protein encoded by the functional gene and its modified product, which is the use in preparing a product for improving the immunity of sea cucumbers;
[0019] The present invention also provides a product for improving the immunity of sea cucumbers, which contains the protein and / or the genetically engineered strain;
[0020] The protein encoded by the functional gene screened and obtained in the present invention has high-efficiency binding activity, agglutination activity and antibacterial activity. The protein produced by the engineered bacteria is placed in the sea cucumber breeding environment to enhance the immunity of the sea cucumber body, which can provide a solution for sea cucumber infection with Vibrio. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The SDS-PAGE electrophoresis diagram of WFDC protein, wherein lane 1 is the pGEX-4T-2 empty vector, lane 2 is the recombinant protein induced for 0 h, lane 3 is the recombinant protein induced for 6 h, and lane 4 is the purified recombinant protein;
[0022] Figure 2 The SDS-PAGE electrophoresis diagram of WFDC-WAP protein, wherein lane 1 is the pGEX-4T-2 empty vector, lane 2 is the recombinant protein induced for 0 h, lane 3 is the recombinant protein induced for 6 h, and lane 4 is the purified recombinant protein;
[0023] Figure 3 This is a diagram for analyzing the binding activity of WFDC protein and WFDC-WAP protein to endotoxin lipopolysaccharide;
[0024] Figure 4 This is a diagram showing the binding activity analysis of WFDC protein and WFDC-WAP protein to endotoxin peptidoglycan;
[0025] Figure 5 This is a diagram showing the binding activity analysis of WFDC protein and WFDC-WAP protein to endotoxin mannan;
[0026] Figure 6 The agglutination effect of WFDC protein on Staphylococcus aureus, Micrococcus luteus, Vibrio splendens and Vibrio parahaemolyticus, where A is TBS-Ca 2+ and bacteria, B is TBS-Ca 2+ , BSA and bacteria, C is TBS-Ca 2+ , recombinant GST-tag protein and bacteria, D is TBS-Ca 2+ -EDTA, recombinant WFDC protein and bacteria, E is TBS-Ca 2+ , recombinant WFDC protein and bacteria;
[0027] Figure 7 The agglutination effect of WFDC-WAP protein on Staphylococcus aureus, Micrococcus luteus, Vibrio splendens and Vibrio parahaemolyticus, where A is TBS-Ca 2+ and bacteria, B is TBS-Ca 2+ , BSA and bacteria, C is TBS-Ca 2+ , recombinant GST-tag protein and bacteria, D is TBS-Ca 2+ -EDTA, recombinant WFDC protein and bacteria, E is TBS-Ca 2+ , recombinant WFDC protein and bacteria;
[0028] Figure 8The figures are the inhibitory effects of WFDC protein on Staphylococcus aureus, Micrococcus luteus, Vibrio splendens and Vibrio parahaemolyticus. In each figure, 1 and 2 are the recombinant protein concentrations of 100 μg / Oxford cup, 3 and 4 are negative control group 1 (sterile culture medium), and 5 and 6 are negative control group 2 (Elution Buffer).
[0029] Fig. 9 The figures show the inhibitory effect of WFDC-WAP protein on Staphylococcus aureus, Micrococcus luteus, Vibrio splendens and Vibrio parahaemolyticus. In each figure, 1 and 2 are the recombinant protein concentrations of 100 μg / Oxford cup, 3 and 4 are negative control group 1 (sterile culture medium), and 5 and 6 are negative control group 2 (Elution Buffer). DETAILED DESCRIPTION
[0030] The present invention discovered EST fragments related to the immune performance of sea cucumbers by high-throughput transcriptome sequencing and expression profile analysis of coelomocytes of sea cucumbers with rotten skin syndrome and healthy sea cucumbers, designed gene-specific primers based on the screened expressed sequence tag EST sequences, and amplified the full length of the gene using RACE technology. Finally, a functional gene was screened from sea cucumbers, and the cDNA sequence of the gene is shown in SEQ ID NO: 1, with a full length of 1112 bp, including an open reading frame of 648 bp (SEQ ID NO: 2), encoding 215 amino acids (SEQ ID NO: 3), a 5' non-coding region of 200 bp, a 3' non-coding region of 264 bp, and a typical poly A tail at the end of the sequence.
[0031]
[0032] The present invention is described in detail below in conjunction with embodiments and drawings.
[0033] Example 1: Gene cloning and sequence analysis
[0034] Through high-throughput transcriptome sequencing and expression profile analysis of the coelomocytes of sea cucumbers with rotten skin syndrome and healthy sea cucumbers, EST fragments related to the immune performance of sea cucumbers were discovered, and based on the EST fragments, nested primers for 3′ RACE were cloned and designed: the sequence of the 3′ upstream specific primer 1 is ATGGGGCAGCCTGTAGTACCGGC, the sequence of the 3′ upstream specific primer 2 is TTGTCGGAATATACAACATCAGG, and the sequence of the 3′ adapter primer Adaptor3 for amplification is GGCCACGCGTCGACTAGTACTT.
[0035] The full-length sequence of the WFDC gene was obtained by 3′ RACE amplification. The specific steps are as follows:
[0036] a. Total RNA extraction: 1 mL of sea cucumber coelomic fluid was taken and centrifuged at 800 g for 5 min. Coelomic cells were collected and 1 mL of Trizol reagent (Takara) was added. The mixture was shaken and mixed. The mixture was placed at room temperature for 5 min. Then 0.2 mL of chloroform was added and shaken and mixed. The mixture was placed at room temperature for 10 min. The mixture was centrifuged at 4°C and 12,000 g for 15 min. The supernatant was transferred to a centrifuge tube and an equal volume of isopropanol was added to the supernatant. The mixture was mixed. The mixture was placed at room temperature for 5 min. The mixture was centrifuged at 4°C and 12,000 g for 10 min. The supernatant was removed. 1 mL of 75% ethanol was added to the precipitate. The mixture was centrifuged at 4°C and 12,000 g for 5 min. The supernatant was removed. The precipitate was placed for 5-10 min. 20 μL of RNase-free water was added to obtain RNA extract.
[0037] b. 3′ RACE amplification: The above RNA extract was amplified using 3′-Full RACE Core Set with PrimeScript TM The RTase kit (Takara) was used to reverse transcribe and synthesize the template for amplification of 3′. The specific synthesis method was performed according to the instructions of the kit. Using this as the template, 3′ upstream specific primer 1 and amplification 3′ adapter primer were used for PCR amplification. 1 μL of PCR product was taken as the template, and then 3′ upstream specific primer 2 and amplification 3′ adapter primer were used for PCR amplification to obtain the 3′ end target band. The RACE amplification reaction system and reaction conditions were as follows: 1 μL template, 10× PCR buffer (containing Mg 2+)2.5μL, 2.5 mM dNTP 2 μL, 10 μM 3′ upstream specific primer 1 μL, 10 μM amplification 3′ adapter primer 1 μL, 5 U / L DNA polymerase 0.2 μL, ultrapure water 17.3 μL: Amplification conditions: 94 ℃ 5 min, 94 ℃ 30 s, 60 ℃ 45 s, 72 ℃ 1 min, a total of 35 cycles, and finally 72 ℃ extension for 10 min;
[0038] c. The target band at the 3′ end of the amplified product was recovered using a gel recovery kit (Biotech), and the recovered product was connected to the vector pMD19-T (Takara) and transformed into Escherichia coli Escherichia coli DH5α (Takara), and then cultured in LB plate medium containing 50 μg / mL ampicillin (LB plate medium formula: tryptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L, agar powder 15 g / L) for 8-12 h, picked the positive clone colonies, performed RCR verification and sent them to Shanghai Shenggong Biotechnology Co., Ltd. for sequencing. The results were analyzed and spliced by DNAMAN software to obtain the full-length sequence of the target gene, which was named WFDC gene.
[0039] The WFDC gene sequence is shown in SEQ ID NO:1. The gene is 1112 bp long, including an open reading frame of 648 bp (SEQ ID NO:2), encoding 215 amino acids (SEQ ID NO:3), a 5′ non-coding region of 200 bp, a 3′ non-coding region of 264 bp, and a typical polyA tail at the end of the sequence. The molecular weight of the encoded protein is 23.717 kDa, and the isoelectric point is 8.34. The WFDC gene sequence was analyzed by the SMART website (http: / / smart.embl-heidelberg.de / ) to determine that the nucleotide sequence of its core fragment WFDC-WAP that exerts antibacterial function is shown in SEQ ID NO:4. The gene fragment is 138 bp long, encoding 46 amino acids (SEQ ID NO:5), and the molecular weight of the encoded protein is 5.341 kDa, and the isoelectric point is 7.75.
[0040] Example 2: Construction and expression of recombinant protein expression vector
[0041] a. Total RNA extraction: Take various tissues of sea cucumber (0.2-1 g) and put them into a 1.5 mL RNA free centrifuge tube, add 1 mL of Trizol reagent (Takara), and homogenize thoroughly with a homogenizer. 4 ℃, 12000 g, centrifuge for 5 min, take the supernatant, add 0.2 mL chloroform, shake and mix, let stand at room temperature for 5 min, 4 ℃, 12000 g, centrifuge for 15 min, aspirate the supernatant into a centrifuge tube, add an equal volume of isopropanol to the supernatant, mix, let stand at room temperature for 5 min, 4 ℃, 12000 g, centrifuge for 5 min, remove the supernatant, add 1 mL of 75% ethanol by mass percentage to the precipitate, 4 ℃, 12000 g, centrifuge for 5 min, discard the supernatant, add 1 mL of 75% ethanol by mass percentage to the precipitate, resuspend the precipitate, 4 ℃, 12000 g, centrifuge for 5 min, remove the supernatant, let the precipitate stand for 5-10 min, add 20 μL of RNase-free water to obtain RNA extraction solution;
[0042] b. cDNA synthesis: The RNA extract was transcribed into cDNA using a cDNA synthesis kit (Takara). The specific synthesis method was performed according to the instructions of the cDNA kit. Then, the synthesized cDNA was amplified by PCR using primers with restriction sites, as shown below:
[0043] Contains Bm I site WFDC upstream amplification primers: GGATCC ATGACAAGGAAAACAATACCC;
[0044] Contains XOt I site WFDC downstream amplification primers: CTCGAG TCAAGGTACTTCTGAAGAGCC;
[0045] Contains Bm I site WFDC-WAP upstream amplification primers: GGATCC CATGAAGGCCAATGCCC;
[0046] Contains XOt I site WFDC-WAP downstream amplification primers: CTCGAG CACAGCCCTTTGACACTTTTT;
[0047] c. PCR amplification: cDNA 1 μL, 10× PCR buffer (containing Mg 2+) 2.5 μL, 10 mM dNTP 2 μL, 10 μM upstream primer 1 μL, 10 μM downstream primer 1 μL, 5 U / L DNA polymerase 0.2 μL, ultrapure water 17.3 μL: Amplification conditions: 94 ℃ 5 min, 94 ℃ 30 s, 58 ℃ 45 s, 72 ℃ 1 min, a total of 35 cycles, and a final extension at 72 ℃ for 10 min;
[0048] d. PCR positive clone plasmid: After amplification, the PCR product was recovered using a gel recovery kit (BioTeke), and then the recovered product was connected to the vector pMD-19T (Takara) and transformed into Escherichia coli. Escherichia coli DH5α (Takara), culture in LB plate medium containing 50 μg / mL ampicillin for 8-12 h, pick positive clones, perform RCR verification and sequencing identification, and obtain the correct positive clone plasmid:
[0049] e. Recombinant plasmid: Recombinant PCR positive cloned plasmid Bm I and XOt The cells were double digested with restriction endonucleases I (New England Biolabs, NEB), and the target bands with molecular weights of 23.717 kDa and 5.341 kDa were recovered by agarose gel electrophoresis and ligated with the prokaryotic expression vector pGEX-4T-2 digested with the same restriction endonucleases to transform Escherichia coli DH5α, PCR screening of positive clones, sequencing identification to obtain the correct coding frame of the expression vector pGEX-4T-2-WFDC and pGEX-4T-2-WFDC-WAP, the positive recombinant plasmids pGEX-4T-2-WFDC and pGEX-4T-2-WFDC-WAP were transformed into the expression host Rosetta (DE3) (Novagen), and then inoculated into LB culture medium (tryptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L) with an ampicillin concentration of 50 μg / mL, 37 ℃, 200 r / min shaking culture until the bacterial solution OD 600 When the value of was 0.4-0.6, isopropyl-BD-thiogalactopyranoside (IPTG) was added to make the final concentration of 1 mmol / L, and the expression was induced at 37 ℃ for 5-6 h. The bacterial solution was collected and centrifuged at 10000 g at 4 ℃ for 5 min. The supernatant was discarded to obtain the bacterial precipitate.
[0050] Example 3: Purification of recombinant protein
[0051] a. Bacterial lysis: resuspend 100 mL of bacterial sediment with 10 mL PBS, add 5 μL TritonX-100, incubate on ice for 30 min, disrupt bacteria with ultrasound, centrifuge at 6000 g, 4 °C for 10 min, collect the precipitate, wash twice with 10 mL Buffer A, wash three times with 10 mL Buffer B, centrifuge at 6000 g, 10 min, resuspend the precipitate with 10 mL 8 M urea, incubate at 37 °C with shaking for 30 min, then centrifuge at 12000 g, 10 min, and collect the supernatant;
[0052] b. Protein refolding and purification: The collected supernatant was placed into an MD34 dialysis bag (Solarbio) and refolded in TBS solution for 48 h. The solution was centrifuged at 12,000 g for 10 min to collect the supernatant. 1 mL of GST-SEFINOSE TM RESIN column, washed twice with sterile water, and balanced once with TBS solution; the collected supernatant was mixed with GST-SEFINOSE treated on the column. TM RESIN, mix at 4 ℃ for 12 h, collect the effluent; elute with Binding / Wash Buffer for GST (Sangong) 3 times, 10 mL each time, collect the effluent respectively; add Elution Buffer (Sangong) 2 mL each time, elute 3 times, collect the effluent respectively, take the effluent eluted with Elution Buffer (Sangong) collected each time for SDS-PAGE electrophoresis identification (the result is shown in Figure 1 ), the target bands with molecular weights of 23.717 kDa and 5.341 kDa were recovered respectively ( Figure 1 and Figure 2 , the arrow indicates the target protein), and recombinant sea cucumber WFDC protein and WFDC-WAP protein were obtained.
[0053] The Buffer A formula is as follows: 50 mM Tris-HCl, 5 mM EDTA, pH=8.0;
[0054] The Buffer B formula is as follows: 50 mM Tris-HCl, 5 mM EDTA, 2 M urea, pH = 8.0;
[0055] The 8 M urea formula is as follows: 0.1 M Tris-HCl, 10 mM DTT, 8 M urea;
[0056] The TBS solution formula is as follows: 3 mM EDTA, 50 mM Tris-HCl, 150 mM NaCl, pH=8.0;
[0057] The specific process of ultrasonic disruption of bacteria is as follows: ultrasonic treatment for 5 s, stop for 10 s, repeat 10 times, and the ultrasonic power is 30 W.
[0058] Example 4: Analysis of endotoxin binding activity of sea cucumber recombinant protein
[0059] a. Three kinds of lipopolysaccharides (Lipopolysaccharides from Escherichia coli 0111: B4, LPS, Sigma), peptidoglycan (PGN, source leaf), mannan (Mannan from Saccharomyces cerevisiae , Sigma) were dissolved in 50 mmol / L, pH = 9.6 carbonate buffer to a final concentration of 2 mg / mL. 20 μL of each of the three endotoxins was added to a 96-well plate, with 5 replicates per group, and incubated at 4 °C overnight;
[0060] b. After the three endotoxins incubated overnight were washed three times with PBST buffer, they were blocked with 200 μL of 5% BSA buffer and incubated at 37 °C for 1 h.
[0061] c. Pour off the BSA buffer of the previous step, wash three times with PBST buffer, add 50 μL of each of the recombinant sea cucumber WFDC protein and WFDC-WAP protein obtained in Specific Example 3, a GST-tagged control protein (GST-tag, 2.0 μg / μL), and a blank control (0.05 M, pH 7.4 Tris-HCl buffer solution TBS) to the three endotoxins, and set 10 different protein concentration gradients according to the WFDC protein concentration (2.0 μg / μL), which are 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, and incubate at 37°C for 1 h;
[0062] d. Wash three times with PBST buffer, add 100 μL Mouse Anti-His Tag monoclonal antibody (1:1000) to each well, and incubate at 37°C for 1 h.
[0063] e. Gently pour out the solution in the previous step, wash three times with PBST, add 100 μL of alkaline phosphatase-labeled goat anti-mouse IgG secondary antibody (1:3000), and incubate at 37 °C for 1 h;
[0064] f. Gently pour out the solution from the previous step, wash 4 times with PBST, add 100 μL PNPP colorimetric solution (Beijing Saichi Biotechnology Co., Ltd.), and incubate at room temperature in the dark for 30 min;
[0065] g. Add 50 μL of 3 mol / L NaOH stop solution to the 96-well plate in the previous step, incubate for 15 min to terminate the reaction, and measure the absorbance of the solution at a wavelength of 405 nm.
[0066] The results show that Figure 3 , Figure 4 and Figure 5 As shown, the recombinant sea cucumber proteins WFDC and WFDC-WAP have significant binding activity to lipopolysaccharide, peptidoglycan and mannan, and the binding activity of WFDC-WAP protein is significantly higher than that of WFDC protein.
[0067] Example 5: Analysis of Agglutination Activity of Sea Cucumber Recombinant Protein
[0068] a. Bacterial FITC labeling: The bacteria to be labeled were cultured to the middle and late exponential growth stages, centrifuged at 5000 g for 10 min at 4 °C, the supernatant was discarded, and the cells were washed twice with PBS (0.01 mol / L, pH = 7.4), centrifuged at 5000 g for 10 min at 4 °C, and then diluted with carbonate buffer to a concentration of 0.5 × 10 9 cfu / mL suspension, add FITC solution (refer to the instructions) to make the final concentration of FITC in the suspension 50-100 μg / mL, stir at room temperature for 1-2 h, centrifuge at 5000 g for 10 min, discard the supernatant, wash twice with PBS, centrifuge at 5000 g for 10 min, take the precipitated bacteria and make it into a concentration of 0.5×10 9 cfu / mL bacterial suspension. After labeling, it was confirmed by fluorescence microscopy and stored at 4 ℃ in the dark.
[0069] b. Use TBS-Ca 2+ Buffer (50 mmol / L Tris-HCl, 50 mmol / L NaCl, 10 mmol / L CaCl2, pH=7.5) and TBS-Ca 2+ FITC-labeled Staphylococcus aureus, Micrococcus luteus, Vibrio splendens, and Vibrio parahaemolyticus were resuspended in EDTA buffer (50 mmol / L Tris-HCl, 50 mmol / L NaCl, 10 mmol / L CaC12, 10 mmol / L EDTA, pH=7.5) to a concentration of 1×10 9 cfu / mL. Take 10 μL TBS-Ca 2+ The buffer-bacterial suspension was mixed with 25 μL BSA (control protein), TBS and recombinant protein WFDC / WFDC-WAP, and the untreated TBS-Ca 2+ The buffer solution-bacterial suspension was used as the control group. 10 μL TBS-Ca2+ -EDTA buffer-bacterial suspension and recombinant protein WFDC / WFDC-WAP were mixed. After incubation at room temperature for 1 h, 10 μL of each of the above samples was dropped onto a glass slide and observed under a fluorescence microscope.
[0070] The results show that Figure 6 and Figure 7 As shown in Figure 2, the recombinant proteins WFDC and WFDC-WAP of sea cucumber had significant Ca inhibition against Staphylococcus aureus, Micrococcus luteus, Vibrio splendens and Vibrio parahaemolyticus. 2+ Dependent agglutination activity.
[0071] Example 6: Analysis of antibacterial activity of recombinant sea cucumber protein
[0072] a. Two positive bacteria tested, Staphylococcus aureus ( Staphylococcus aureus ), Micrococcus luteus ( Micrococcus luteus ) was inoculated into LB liquid medium (tryptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L) and cultured at 37 °C and 150 r / min until OD 600 =1.0, take 100 μL of bacterial solution and spread on a plate (agar 12 g / mL);
[0073] b. Two negative bacteria tested, Vibrio splendens ( Vibrio splendidus ), Vibrio parahaemolyticus ( Vibrio parahaemolyticus ) was inoculated into 2216E liquid medium (tryptone 5 g / L, yeast extract 1 g / L) and cultured at 28 °C and 150 r / min until OD 600 =1.0, 150 r / min, culture until OD 600 =1.0, take 100 μL of bacterial solution and spread on a plate (agar 12 g / mL);
[0074] c. The antibacterial activity of the recombinant protein was determined by the modified agar plate diffusion method (Oxford cup). For each test bacteria, a recombinant protein experimental group (1 and 2), a negative control group 1 (3 and 4, sterile LB / 2216E liquid culture medium), and a negative control group 2 (5 and 6, Elution Buffer) were set. A sterile Oxford cup (diameter 0.8 cm) was placed in the above-mentioned plate, and different mass concentrations of 100 μg / Oxford cup were added to each Oxford cup in turn. Specific Example 3 The recombinant sea cucumber WFDC protein / WFDC-WAP protein constructed and an equal volume of negative control group 1 (sterile LB / 2216E liquid culture medium) and negative control group 2 (Elution Buffer) were added. The Staphylococcus aureus and Micrococcus luteus experimental groups were cultured at 37°C for 12 h, and the Vibrio splendens and Vibrio parahaemolyticus experimental groups were cultured at 28°C for 12 h, and the diameter of the inhibition zone was observed and measured.
[0075] The results showed that the recombinant sea cucumber WFDC protein constructed in Specific Example 3 had a good inhibitory effect on Gram-positive bacteria Staphylococcus aureus and Micrococcus luteus, but a poor inhibitory effect on Gram-negative bacteria Vibrio splendens and Vibrio parahaemolyticus ( Figure 8 ), wherein the antibacterial diameter of the recombinant protein against Staphylococcus aureus is 2.45 ± 0.11 cm, the antibacterial diameter of the recombinant protein against Micrococcus luteus is 2.42 ± 0.22 cm, the antibacterial diameter of the recombinant protein against Vibrio splendens is 1.57 ± 0.09 cm, and the antibacterial diameter of the recombinant protein against Vibrio parahaemolyticus is 1.62 ± 0.11 cm. In order to solve this problem, the core amino acid sequence (SEQ ID NO: 5) of the WFDC protein that exerts an antibacterial function was analyzed and selected using the SMART website. The purified recombinant WFDC-WAP protein was obtained by the above method. The results of the antibacterial activity analysis showed that the recombinant sea cucumber WFDC-WAP protein constructed in Specific Example 3 had obvious antibacterial effects on Gram-positive bacteria Staphylococcus aureus and Micrococcus luteus and Gram-negative bacteria Vibrio splendens and Vibrio parahaemolyticus ( Fig. 9 ), compared with WFDC protein, it especially improved the antibacterial activity against Gram-negative bacteria Vibrio splendens and Vibrio parahaemolyticus. Among them, the antibacterial diameter of the recombinant protein against Staphylococcus aureus was 2.83 ± 0.15 cm, the antibacterial diameter of the recombinant protein against Micrococcus luteus was 2.81 ± 0.12 cm, the antibacterial diameter of the recombinant protein against Vibrio splendens was 2.24 ± 0.10 cm, and the antibacterial diameter of the recombinant protein against Vibrio parahaemolyticus was 2.20 ± 0.23 cm.
[0076] The above description is not intended to limit the present invention, and the present invention is not limited to the above examples. Any changes, modifications, additions or substitutions made by a person skilled in the art within the spirit and scope of the present invention shall also fall within the protection scope of the present invention.
Claims
1. A functional gene, characterized in that: The amino acid sequence of the protein encoded by the functional gene is SEQ ID NO:
3.
2. The functional gene according to claim 1, characterized in that The nucleic acid sequence of the CDS of the gene is SEQ ID NO:
2.
3. The functional gene modification according to claim 1, characterized in that: The amino acid sequence of the protein encoded by the transformant is SEQ ID NO:
5.
4. The modified body according to claim 3, characterized in that: The nucleic acid sequence of CDS of the transformant is SEQ ID NO:
4.
5. A recombinant expression vector, characterized in that: The functional gene according to claim 1 or the CDS nucleic acid fragment of the transformed body according to claim 3 is inserted into the recombinant expression vector.
6. A genetically engineered strain, characterized in that: The genetically engineered strain carries the recombinant expression vector described in claim 5.
7. Use of the protein encoded by the functional gene according to claim 1 or the protein encoded by the modified body according to claim 3 as an endotoxin lipopolysaccharide, peptidoglycan or mannan binder.
8. Use of the protein encoded by the functional gene according to claim 1 or the protein encoded by the modified body according to claim 3 in the preparation of a product for inhibiting bacteria.
